Risk assessment in haematopoietic stem cell transplantation: GvHD prevention and treatment

Best Practice and Research: Clinical Haematology

Volumn 20, Issue 2, 2007, Pages 281-294

  Holler, Ernst ^a  

^a UNIVERSITY HOSPITAL REGENSBURG   (Germany)

Author keywords

calcineurin inhibitors; corticosteroids; graft versus host disease; graft versus leukaemia

Indexed keywords

BECLOMETASONE; CALCINEURIN INHIBITOR; CD3 ANTIBODY; CD3 ANTIGEN; CD34 ANTIGEN; CD5 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; DACLIZUMAB; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHOTREXATE; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PENTOSTATIN; POLYCLONAL ANTIBODY; RAPAMYCIN; RITUXIMAB; TACROLIMUS; THALIDOMIDE; THYMOCYTE ANTIBODY;

ACUTE GRAFT VERSUS HOST DISEASE; ANTIGEN SPECIFICITY; APLASTIC ANEMIA; ASPERGILLOSIS; BONE MARROW SUPPRESSION; BONE NECROSIS; CATARACT; CD34 SELECTION; CELL AGGLUTINATION; CHRONIC GRAFT VERSUS HOST DISEASE; CHRONIC MYELOID LEUKEMIA; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ELUTION; ENDOTHELIAL DYSFUNCTION; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HYPERTENSION; INFECTION; KIDNEY DISEASE; MEDICAL DECISION MAKING; MESENCHYMAL STEM CELL TRANSPLANTATION; META ANALYSIS; METABOLIC DISORDER; MICROANGIOPATHY; MONOTHERAPY; MORBIDITY; MORTALITY; MUCOSA INFLAMMATION; NEUROLOGIC DISEASE; NEUTROPENIA; NONMYELOABLATIVE CONDITIONING; OVERALL SURVIVAL; PRIORITY JOURNAL; PUVA; QUALITY OF LIFE; RECURRENCE RISK; REDUCED INTENSITY CONDITIONING; REVIEW; RISK ASSESSMENT; SOYBEAN; SYSTEMATIC REVIEW; T CELL DEPLETION; TREATMENT OUTCOME; TREMOR; VIRUS INFECTION;

ACUTE DISEASE; ADRENAL CORTEX HORMONES; CALCINEURIN; CHRONIC DISEASE; CYCLOSPORINE; GRAFT VS HOST DISEASE; GRAFT VS LEUKEMIA EFFECT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; METHOTREXATE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; RISK ASSESSMENT; T-LYMPHOCYTES; TACROLIMUS;

EID: 34247158560     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2006.10.001     Document Type: Review

References (95)

1. Horowitz M.M., Gale R.P., Sondel P.M., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75 (1990) 555-562
2. Gratwohl A., Brand R., Apperley J., et al. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia. Blood 100 (2002) 3877-3886
3. Goulmy E. Minor histocompatibility antigens: allo target molecules for tumor-specific immunotherapy. Cancer Journal (Sudbury, Mass.) 10 (2004) 1-7
4. Riddell S.R., Berger C., Murata M., et al. The graft versus leukemia response after allogeneic hematopoietic stem cell transplantation. Blood Reviews 17 (2003) 153-162
5. Deeg H.J., Lin D., Leisenring W., et al. Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial. Blood 89 (1997) 3880-3887
6. Storb R., Deeg H.J., Fisher L., et al. Cyclosporine v methotrexate for graft-v-host disease prevention in patients given marrow grafts for leukemia: long-term follow-up of three controlled trials. Blood 71 (1988) 293-298
7. Sorror M.L., Leisenring W., Deeg H.J., et al. Twenty-year follow-up of a controlled trial comparing a combination of methotrexate plus cyclosporine with cyclosporine alone for prophylaxis of graft-versus-host disease in patients administered HLA-identical marrow grafts for leukemia. Biology of Blood and Marrow Transplantation 11 (2005) 814-815
8. Storb R., Deeg H.J., Whitehead J., et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. The New England Journal of Medicine 314 (1986) 729-735
9. Locatelli F., Bruno B., Zecca M., et al. Cyclosporin A and short-term methotrexate versus cyclosporin A as graft versus host disease prophylaxis in patients with severe aplastic anemia given allogeneic bone marrow transplantation from an HLA-identical sibling: results of a GITMO/EBMT randomized trial. Blood 96 (2000) 1690-1697
10. Weaver C.H., Clift R.A., Deeg H.J., et al. Effect of graft-versus-host disease prophylaxis on relapse in patients transplanted for acute myeloid leukemia. Bone Marrow Transplantation 14 (1994) 885-893
11. Locatelli F., Zecca M., Rondelli R., et al. Graft versus host disease prophylaxis with low-dose cyclosporine-A reduces the risk of relapse in children with acute leukemia given HLA-identical sibling bone marrow transplantation: results of a randomized trial. Blood 95 (2000) 1572-1579
12. Loughran Jr. T.P., Deeg H.J., Dahlberg S., et al. Incidence of hypertension after marrow transplantation among 112 patients randomized to either cyclosporine or methotrexate as graft-versus-host disease prophylaxis. British Journal of Haematology 59 (1985) 547-553
13. Holler E., Kolb H.J., Hiller E., et al. Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation. Blood 73 (1989) 2018-2024
14. Nash R.A., Antin J.H., Karanes C., et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 96 (2000) 2062-2068
15. Ratanatharathorn V., Nash R.A., Przepiorka D., et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 92 (1998) 2303-2314
16. Yanada M., Emi N., Naoe T., et al. Tacrolimus instead of cyclosporine used for prophylaxis against graft-versus-host disease improves outcome after hematopoietic stem cell transplantation from unrelated donors, but not from HLA-identical sibling donors: a nationwide survey conducted in Japan. Bone Marrow Transplantation 34 (2004) 331-337
17. Antin J.H., Kim H.T., Cutler C., et al. Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantation. Blood 102 (2003) 1601-1605
18. Benito A.I., Furlong T., Martin P.J., et al. Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease. Transplantation 72 (2001) 1924-1929
19. Cutler C., Kim H.T., Hochberg E., et al. Sirolimus and tacrolimus without methotrexate as graft-versus-host disease prophylaxis after matched related donor peripheral blood stem cell transplantation. Biology of Blood and Marrow Transplantation 10 (2004) 328-336
20. Atkinson K., Biggs J., Concannon A., et al. A prospective randomised trial of cyclosporin and methotrexate versus cyclosporin, methotrexate and prednisolone for prevention of graft-versus-host disease after HLA-identical sibling marrow transplantation for haematological malignancy. Australian and New Zealand Journal of Medicine 21 (1991) 850-856
21. Chao N.J., Schmidt G.M., Niland J.C., et al. Cyclosporine, methotrexate, and prednisone compared with cyclosporine and prednisone for prophylaxis of acute graft-versus-host disease. The New England Journal of Medicine 329 (1993) 1225-1230
22. Chao N.J., Snyder D.S., Jain M., et al. Equivalence of 2 effective graft-versus-host disease prophylaxis regimens: results of a prospective double-blind randomized trial. Biology of Blood and Marrow Transplantation 6 (2000) 254-261
23. Ruutu T., Volin L., Parkkali T., et al. Cyclosporine, methotrexate, and methylprednisolone compared with cyclosporine and methotrexate for the prevention of graft-versus-host disease in bone marrow transplantation from HLA-identical sibling donor: a prospective randomized study. Blood 96 (2000) 2391-2398
24. Basara N., Blau W.I., Kiehl M.G., et al. Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients. Clinical Transplantation 14 (2000) 121-126
25. Nash R.A., Johnston L., Parker P., et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biology of Blood and Marrow Transplantation 11 (2005) 495-505
26. Vogelsang G.B., and Arai S. Mycophenolate mofetil for the prevention and treatment of graft-versus-host disease following stem cell transplantation: preliminary findings. Bone Marrow Transplantation 27 (2001) 1255-1262
27. Bolwell B., Sobecks R., Pohlman B., et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplantation 34 (2004) 621-625
28. Mohty M., de Lavallade H., Faucher C., et al. Mycophenolate mofetil and cyclosporine for graft-versus-host disease prophylaxis following reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplantation 34 (2004) 527-530
29. Neumann F., Graef T., Tapprich C., et al. Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplantation 35 (2005) 1089-1093
30. Marmont A.M., Horowitz M.M., Gale R.P., et al. T-cell depletion of HLA-identical transplants in leukemia. Blood 78 (1991) 2120-2130
31. O'Reilly R.J., Brochstein J., Collins N., et al. Evaluation of HLA-haplotype disparate parental marrow grafts depleted of T lymphocytes by differential agglutination with a soybean lectin and E-rosette depletion for the treatment of severe combined immunodeficiency. Vox Sanguinis 51 supplement 2 (1986) 81-86
32. Platzbecker U., Ehninger G., and Bornhauser M. Allogeneic transplantation of CD34+ selected hematopoietic cells-clinical problems and current challenges. Leukemia & Lymphoma 45 (2004) 447-453
33. Urbano-Ispizua A., Rozman C., Martinez C., et al. Rapid engraftment without significant graft-versus-host disease after allogeneic transplantation of CD34+ selected cells from peripheral blood. Blood 89 (1997) 3967-3973
34. Wagner J.E., Thompson J.S., Carter S.L., et al. Effect of graft-versus-host disease prophylaxis on 3-year disease-free survival in recipients of unrelated donor bone marrow (T-cell Depletion Trial): a multi-centre, randomised phase II-III trial. Lancet 366 (2005) 733-741
35. Ash R.C., Casper J.T., Chitambar C.R., et al. Successful allogeneic transplantation of T-cell-depleted bone marrow from closely HLA-matched unrelated donors. The New England Journal of Medicine 322 (1990) 485-494
36. Bacigalupo A., Lamparelli T., Bruzzi P., et al. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood 98 (2001) 2942-2947
37. Barge R.M., Starrenburg C.W., Falkenburg J.H., et al. Long-term follow-up of myeloablative allogeneic stem cell transplantation using Campath 'in the bag' as T-cell depletion: the Leiden experience. Bone Marrow Transplantation 37 (2006) 1129-1134
38. Martin P.J., Hansen J.A., Torok-Storb B., et al. Effects of treating marrow with a CD3-specific immunotoxin for prevention of acute graft-versus-host disease. Bone Marrow Transplantation 3 (1988) 437-444
39. Ringden O., Remberger M., Aschan J., et al. Long-term follow-up of a randomized trial comparing T cell depletion with a combination of methotrexate and cyclosporine in adult leukemic marrow transplant recipients. Transplantation 58 (1994) 887-891
40. Chalandon Y., Roosnek E., Mermillod B., et al. Can only partial T-cell depletion of the graft before hematopoietic stem cell transplantation mitigate graft-versus-host disease while preserving a graft-versus-leukemia reaction? A prospective phase II study. Biology of Blood and Marrow Transplantation 12 (2006) 102-110
41. Goerner M., Weber-Nordt R., Hoepfner S., et al. Addition of a low fixed number of CD3+ cells to CD34-enriched allografts: effects on engraftment, graft-versus-host disease, and survival after related and unrelated peripheral stem cell transplantation. Journal of Hematotherapy & Stem Cell Research 12 (2003) 309-320
42. Ho V.T., Kim H.T., Li S., et al. Partial CD8+ T-cell depletion of allogeneic peripheral blood stem cell transplantation is insufficient to prevent graft-versus-host disease. Bone Marrow Transplantation 34 (2004) 987-994
43. Champlin R.E., Passweg J.R., Zhang M.J., et al. T-cell depletion of bone marrow transplants for leukemia from donors other than HLA-identical siblings: advantage of T-cell antibodies with narrow specificities. Blood 95 (2000) 3996-4003
44. Elmaagacli A.H., Peceny R., Steckel N., et al. Outcome of transplantation of highly purified peripheral blood CD34+ cells with T-cell add-back compared with unmanipulated bone marrow or peripheral blood stem cells from HLA-identical sibling donors in patients with first chronic phase chronic myeloid leukemia. Blood 101 (2003) 446-453
45. Martin P.J., Pei J., Gooley T., et al. Evaluation of a CD25-specific immunotoxin for prevention of graft-versus-host disease after unrelated marrow transplantation. Biology of Blood and Marrow Transplantation 10 (2004) 552-560
46. Davies J.K., Koh M.B., and Lowdell M.W. Antiviral immunity and T-regulatory cell function are retained after selective alloreactive T-cell depletion in both the HLA-identical and HLA-mismatched settings. Biology of Blood and Marrow Transplantation 10 (2004) 259-268
47. Solomon S.R., Mielke S., Savani B.N., et al. Selective depletion of alloreactive donor lymphocytes: a novel method to reduce the severity of graft-versus-host disease in older patients undergoing matched sibling donor stem cell transplantation. Blood 106 (2005) 1123-1129
48. Navari R.M., Buckner C.D., Clift R.A., et al. Prophylaxis of infection in patients with aplastic anemia receiving allogeneic marrow transplants. The American Journal of Medicine 76 (1984) 564-572
49. Beelen D.W., Haralambie E., Brandt H., et al. Evidence that sustained growth suppression of intestinal anaerobic bacteria reduces the risk of acute graft-versus-host disease after sibling marrow transplantation. Blood 80 (1992) 2668-2676
50. Beelen D.W., Elmaagacli A., Muller K.D., et al. Influence of intestinal bacterial decontamination using metronidazole and ciprofloxacin or ciprofloxacin alone on the development of acute graft-versus-host disease after marrow transplantation in patients with hematologic malignancies: final results and long-term follow-up of an open-label prospective randomized trial. Blood 93 (1999) 3267-3275
51. Feinstein L.C., Seidel K., Jocum J., et al. Reduced dose intravenous immunoglobulin does not decrease transplant-related complications in adults given related donor marrow allografts. Biology of Blood and Marrow Transplantation 5 (1999) 369-378
52. Winston D.J., Antin J.H., Wolff S.N., et al. A multicenter, randomized, double-blind comparison of different doses of intravenous immunoglobulin for prevention of graft-versus-host disease and infection after allogeneic bone marrow transplantation. Bone Marrow Transplantation 28 (2001) 187-196
53. Elmaagacli A.H., Koldehoff M., Hindahl H., et al. Mutations in innate immune system NOD2/CARD 15 and TLR-4 (Thr399Ile) genes influence the risk for severe acute graft-versus-host disease in patients who underwent an allogeneic transplantation. Transplantation 81 (2006) 247-254
54. Holler E., Rogler G., Herfarth H., et al. Both donor and recipient NOD2/CARD15 mutations associate with transplant-related mortality and GvHD following allogeneic stem cell transplantation. Blood 104 (2004) 889-894
55. Holler E., Rogler G., Brenmoehl J., et al. Prognostic significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem cell transplantation: effect on long-term outcome is confirmed in 2 independent cohorts and may be modulated by the type of gastrointestinal decontamination. Blood 107 (2006) 4189-4193
56. Martin P.J., Schoch G., Fisher L., et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 76 (1990) 1464-1472
57. Weisdorf D., Haake R., Blazar B., et al. Treatment of moderate/severe acute graft-versus-host disease after allogeneic bone marrow transplantation: an analysis of clinical risk features and outcome. Blood 75 (1990) 1024-1030
58. Doney K.C., Weiden P.L., Storb R., et al. Treatment of graft-versus-host disease in human allogeneic marrow graft recipients: a randomized trial comparing antithymocyte globulin and corticosteroids. American Journal of Hematology 11 (1981) 1-8
59. Kennedy M.S., Deeg H.J., Storb R., et al. Treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Randomized study comparing corticosteroids and cyclosporine. The American Journal of Medicine 78 (1985) 978-983
60. Marr K.A., Carter R.A., Boeckh M., et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100 (2002) 4358-4366
61. Socie G., Selimi F., Sedel L., et al. Avascular necrosis of bone after allogeneic bone marrow transplantation: clinical findings, incidence and risk factors. British Journal of Haematology 86 (1994) 624-628
62. Ruutu T., Hermans J., van Biezen A., et al. How should corticosteroids be used in the treatment of acute GVHD? EBMT Chronic Leukemia Working Party. European Group for Blood and Marrow Transplantation. Bone Marrow Transplantation 22 (1998) 614-615
63. Hings I.M., Filipovich A.H., Miller W.J., et al. Prednisone therapy for acute graft-versus-host disease: short- versus long-term treatment. A prospective randomized trial. Transplantation 56 (1993) 577-580
64. Cragg L., Blazar B.R., Defor T., et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biology of Blood and Marrow Transplantation 6 (2000) 441-447
65. Martin P.J., Nelson B.J., Appelbaum F.R., et al. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 88 (1996) 824-830
66. Cahn J.Y., Bordigoni P., Tiberghien P., et al. Treatment of acute graft-versus-host disease with methylprednisolone and cyclosporine with or without an anti-interleukin-2 receptor monoclonal antibody. A multicenter phase III study. Transplantation 60 (1995) 939-942
67. Uberti J.P., Ayash L., Ratanatharathorn V., et al. Pilot trial on the use of etanercept and methylprednisolone as primary treatment for acute graft-versus-host disease. Biology of Blood and Marrow Transplantation 11 (2005) 680-687
68. McDonald G.B., Bouvier M., Hockenbery D.M., et al. Oral beclomethasone dipropionate for treatment of intestinal graft-versus-host disease: a randomized, controlled trial. Gastroenterology 115 (1998) 28-35
69. Martin P.J., Schoch G., Fisher L., et al. A retrospective analysis of therapy for acute graft-versus-host disease: secondary treatment. Blood 77 (1991) 1821-1828
70. van Lint M.T., Milone G., Leotta S., et al. Treatment of acute graft-versus-host disease with prednisolone: significant survival advantage for day +5 responders and no advantage for nonresponders receiving anti-thymocyte globulin. Blood 107 (2006) 4177-4181
71. Basara N., Blau W.I., Romer E., et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplantation 22 (1998) 61-65
72. Furlong T., Storb R., Anasetti C., et al. Clinical outcome after conversion to FK 506 (tacrolimus) therapy for acute graft-versus-host disease resistant to cyclosporine or for cyclosporine-associated toxicities. Bone Marrow Transplantation 26 (2000) 985-991
73. Carpenter P.A., Appelbaum F.R., Corey L., et al. A humanized non-FcR-binding anti-CD3 antibody, visilizumab, for treatment of steroid-refractory acute graft-versus-host disease. Blood 99 (2002) 2712-2719
74. Knop S., Hebart H., Gscheidle H., et al. OKT3 muromonab as second-line and subsequent treatment in recipients of stem cell allografts with steroid-resistant acute graft-versus-host disease. Bone Marrow Transplantation 36 (2005) 831-837
75. Cuthbert R.J., Phillips G.L., Barnett M.J., et al. Anti-interleukin-2 receptor monoclonal antibody (BT 563) in the treatment of severe acute GVHD refractory to systemic corticosteroid therapy. Bone Marrow Transplantation 10 (1992) 451-455
76. Przepiorka D., Kernan N.A., Ippoliti C., et al. Daclizumab, a humanized anti-interleukin-2 receptor alpha chain antibody, for treatment of acute graft-versus-host disease. Blood 95 (2000) 83-89
77. Antin J.H., Weinstein H.J., Guinan E.C., et al. Recombinant human interleukin-1 receptor antagonist in the treatment of steroid-resistant graft-versus-host disease. Blood 84 (1994) 1342-1348
78. Herve P., Racadot E., Wijdenes J., et al. Monoclonal anti TNF alpha antibody in the treatment of acute GvHD refractory both to corticosteroids and anti IL-2 R antibody. Bone Marrow Transplantation 7 supplement 2 (1991) 149
79. Couriel D., Saliba R., Hicks K., et al. Tumor necrosis factor-alpha blockade for the treatment of acute GVHD. Blood 104 (2004) 649-654
80. Marty F.M., Lee S.J., Fahey M.M., et al. Infliximab use in patients with severe graft-versus-host disease and other emerging risk factors of non-Candida invasive fungal infections in allogeneic hematopoietic stem cell transplant recipients: a cohort study. Blood 102 (2003) 2768-2776
81. Wolff D., Roessler V., Steiner B., et al. Treatment of steroid-resistant acute graft-versus-host disease with daclizumab and etanercept. Bone Marrow Transplantation 35 (2005) 1003-1010
82. Furlong T., Leisenring W., Storb R., et al. Psoralen and ultraviolet A irradiation (PUVA) as therapy for steroid-resistant cutaneous acute graft-versus-host disease. Biology of Blood and Marrow Transplantation 8 (2002) 206-212
83. Greinix H.T., Volc-Platzer B., Kalhs P., et al. Extracorporeal photochemotherapy in the treatment of severe steroid-refractory acute graft-versus-host disease: a pilot study. Blood 96 (2000) 2426-2431
84. Greinix H.T., Volc-Platzer B., and Knobler R.M. Extracorporeal photochemotherapy in the treatment of severe graft-versus-host disease. Leukemia & Lymphoma 36 (2000) 425-434
85. Greinix H.T., Knobler R.M., Worel N., et al. The effect of intensified extracorporeal photochemotherapy on long-term survival in patients with severe acute graft-versus-host disease. Haematologica 91 (2006) 405-408
86. Hoffmann P., and Edinger M. CD4+CD25+ regulatory T cells and graft-versus-host disease. Seminars in Hematology 43 (2006) 62-69
87. Ringden O., Uzunel M., Rasmusson I., et al. Mesenchymal stem cells for treatment of therapy-resistant graft-versus-host disease. Transplantation 81 (2006) 1390-1397
88. Le Blanc K., Rasmusson I., Sundberg B., et al. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363 (2004) 1439-1441
89. Kulkarni S., Powles R., Treleaven J., et al. Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants. Blood 95 (2000) 3683-3686
90. Couriel D., Carpenter P.A., Cutler C., et al. Ancillary therapy and supportive care of chronic graft-versus-host disease: national institutes of health consensus development project on criteria for clinical trials in chronic Graft-versus-host disease: V. Ancillary Therapy and Supportive Care Working Group Report. Biology of Blood and Marrow Transplantation 12 (2006) 375-396
91. Koc S., Leisenring W., Flowers M.E., et al. Therapy for chronic graft-versus-host disease: a randomized trial comparing cyclosporine plus prednisone versus prednisone alone. Blood 100 (2002) 48-51
92. Sullivan K.M., Witherspoon R.P., Storb R., et al. Alternating-day cyclosporine and prednisone for treatment of high-risk chronic graft-v-host disease. Blood 72 (1988) 555-561
93. Goldberg J.D., Jacobsohn D.A., Margolis J., et al. Pentostatin for the treatment of chronic graft-versus-host disease in children. Journal Of Pediatric Hematology/Oncology 25 (2003) 584-588
94. Arora M., Wagner J.E., Davies S.M., et al. Randomized clinical trial of thalidomide, cyclosporine, and prednisone versus cyclosporine and prednisone as initial therapy for chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation 7 (2001) 265-273
95. Cutler C., Miklos D., Kim H.T., et al. Rituximab for steroid-refractory chronic graft-versus-host disease. Blood 108 (2006) 756-762